Zokinvy(lonafarnib)
Zokinvy (lonafarnib) is a small molecule pharmaceutical. Lonafarnib was first approved as Zokinvy on 2020-11-20. It has been approved in Europe to treat laminopathies and progeria. It is known to target GTPase HRas, GTPase KRas, and GTPase NRas.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Zokinvy
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lonafarnib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZOKINVY | Sentynl Therapeutics | N-213969 RX | 2020-11-20 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lonafarnib | New Drug Application | 2020-12-04 |
| zokinvy | New Drug Application | 2025-07-02 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LONAFARNIB, ZOKINVY, EIGER BIOPHARMS | |||
| 2027-11-20 | ODE-324 | ||
| 2025-11-20 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis d | D019701 | — | — | — | 2 | 2 | — | — | 4 |
| Hepatitis d | D003699 | EFO_0007304 | — | — | — | 2 | — | — | 2 |
| Hepatitis b | D006509 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis | D006521 | — | K73.9 | — | 2 | — | — | — | 2 |
| Progeria | D011371 | EFO_0000671 | E34.8 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Laminopathies | D000083083 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lonafarnib |
| INN | lonafarnib |
| Description | Lonafarnib is a 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor. It has a role as an antineoplastic agent and an EC 2.5.1.58 (protein farnesyltransferase) inhibitor. |
| Classification | Small molecule |
| Drug class | farnesyl transferase inhibitor |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 193275-84-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL298734 |
| ChEBI ID | — |
| PubChem CID | 148195 |
| DrugBank | DB06448 |
| UNII ID | IOW153004F (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HRAS
HRAS
KRAS
KRAS
Organism
Homo sapiens
Gene name
HRAS
Gene synonyms
HRAS1
NCBI Gene ID
Protein name
GTPase HRas
Protein synonyms
c-H-ras, c-has/bas p21 protein, GTP- and GDP-binding peptide B, H-Ras-1, Ha-Ras, Ha-Ras1 proto-oncoprotein, Harvey rat sarcoma viral oncogene homolog, Harvey rat sarcoma viral oncoprotein, p19 H-RasIDX protein, p21ras, Ras family small GTP binding protein H-Ras, transformation gene: oncogene HAMSV, Transforming protein p21, v-Ha-ras Harvey rat sarcoma viral oncogene homolog
Uniprot ID
Mouse ortholog
Hras (15461)
GTPase HRas (Q811B9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,630 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
104 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use